RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) has announced the issuance of inducement stock options to a new employee, as part of the company’s strategic compensation approach. The company’s Board of Directors’ Compensation Committee approved these non-qualified stock options to purchase 9,800 shares of Marinus’ common stock, aligning with Nasdaq Listing Rule 5635(c)(4).
The stock options have been priced at $1.85 per share, reflecting the closing price of Marinus’ common stock on October 7, 2024. This grant is structured as an inducement for the new employee to join the company, providing a direct incentive tied to the company’s performance.
The vesting schedule for these options is designed to promote long-term engagement with Marinus. Initially, 25% of the options will vest and become exercisable after one year of employment. The remaining 75% of the options will vest in equal monthly installments over the next three years, contingent on the employee’s continued service with the company.
This strategic move by Marinus aligns with its commitment to attract and retain top talent, ensuring new employees are invested in the company’s future success. The grants are governed by the terms of the respective award agreement, underscoring a structured approach to employee incentives.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.